Sage Therapeutics. has been granted a patent for a compound of Formula (I) and its pharmaceutically acceptable salts, aimed at treating CNS-related disorders. The patent includes specific structural definitions and potential pharmaceutical compositions utilizing these compounds. GlobalData’s report on Sage Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sage Therapeutics, Anti-inflammatory anesthetics was a key innovation area identified from patents. Sage Therapeutics's grant share as of June 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US11999765B2 outlines a series of claims related to specific chemical compounds, particularly those represented by Formula (I-v) and its derivatives. The claims detail various configurations of these compounds, including the presence of substituents such as R55c and Ra, which can take on specific forms, including hydrogen, cyano groups, or unsubstituted C1-6 alkyl groups. The claims also specify conditions under which these compounds can exist, such as the integer value of p being equal to 1. Additionally, the patent encompasses pharmaceutically acceptable salts of these compounds, indicating their potential utility in therapeutic applications.
Further claims elaborate on the structural variations of the compounds, including references to additional formulas (I-Iw1 and I-Ix1) that fall under the broader category of Formula (I-v). The claims emphasize the importance of specific substituents and their configurations, which may influence the compounds' biological activity or stability. The patent also includes a claim for a pharmaceutical composition that combines the identified compounds with acceptable excipients, suggesting a focus on developing formulations for potential medical use. Overall, the patent presents a detailed framework for the synthesis and application of these chemical entities in pharmaceutical contexts.
To know more about GlobalData’s detailed insights on Sage Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
